Abstract
Lifetime glycemic exposure or its relationship with age at diagnosis (AAD) in type 2 diabetes (T2D) is unknown. We studied how AAD of T2D affects glycemic exposure, glycemic deterioration and responses to oral glucose-lowering drugs (OGLDs).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
